I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

Rhea-AI Summary

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, will announce its financial results for the full year ended December 31, 2022 on March 31, 2023. The report will be released before the market opens, followed by a conference call for investors and analysts at 8:15 a.m. EST. I-Mab focuses on the discovery and development of novel biologics, with over 10 candidates in its pipeline. The company aims to bring innovative medicines to patients globally, leveraging both internal research and partnerships.

Positive

• Over 10 clinical and pre-clinical drug candidates in the pipeline.
• Focus on transformational medicines in immuno-oncology and autoimmune diseases.

Negative

• None.

GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.

I-Mab Conference Call Information

Investors and analysts are invited to join the conference call at 8:15 a.m. EST on March 31 via Zoom:
Link: https://i-mabbiopharma.zoom.us/j/85207042705?pwd=WUpJTjl1b1VUZlFKNHVRa3A4akxtZz09 
Meeting ID:    852 0704 2705
Password:       782962

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies through internal R&D and global partnerships and commercial partnerships. I-Mab has established its global footprint in Shanghai, Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.  For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

I-Mab Contacts

Richard Yeh Chief Operating Officer, interim Chief Financial Officer IR@i-mabbiopharma.com		Gigi Feng Chief Communications Officer PR@i-mabbiopharma.com

Investor Inquiries

The Piacente Group, Inc. Emilie Wu E-mail: emilie@thepiacentegroup.com Office line: +86 21 6039 8363

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-report-full-year-2022-financial-results-and-provide-corporate-update-on-march-31-2023-301776015.html

SOURCE I-Mab

FAQ

When will I-Mab report its financial results for 2022?

I-Mab will report its financial results for the full year ended December 31, 2022, on March 31, 2023.

What time is the I-Mab conference call scheduled for?

The I-Mab conference call is scheduled for 8:15 a.m. EST on March 31, 2023.

What is I-Mab focused on regarding drug development?

I-Mab focuses on the discovery and development of novel biologics in immuno-oncology and autoimmune diseases.

Where can I find more information about I-Mab?

More information about I-Mab can be found on their official website at http://www.i-mabbiopharma.com.